

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|-------------------------------------|---|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted <i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

- | | |
|-----------------|---|
| Data collection | The datasets were collected EPU 1.9 software on FEI Titan Krios (FEI/Thermofischer) transmission electron microscope operated at 300 keV with a slit width of 20 eV on a GIF quantum energy filter (Gatan). A K2 Summit detector (Gatan) was used at a pixel size of 0.83 Å (magnification of 165,000x) with an exposure rate of 4.26 electrons/pixel/second fractionated over 20 frames. A defocus range of 0.6 to 2.6 μm was used. Tomography data were collected with SerialEM 4.0 |
| Data analysis | Movie frames were aligned and averaged by global and local motion corrections by the program RELION-3.1. Contrast transfer function (CTF) parameters were estimated by CTFIND4. Particles were picked and initially 2D classified by RELION 3.1. 2D classification and 3D heterogeneous refinement steps were performed in cryoSPARC v.2.0. The models were manually built with Coot 0.95 and stereochemical refinement was performed using phenix.real_space_refine in the PHENIX 1.19 suite. The final model was validated using MolProbity 4.2. Simulation data analysis is done with GROMACS tools and Visual Molecular Dynamics (VMD 1.9.3 - 1.9.5), Martini3, martinize2 (version 2.6). Tilt series was performed in IMOD 4.1.1. Subtomogram averaging was performed in PEET 1.9.0. |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The atomic coordinates were deposited in the RCSB Protein Data Bank (PDB) under accession numbers 8BQS (supercomplex), 8B6F (CI), 8B6G (CII), 8B6H (CIV), 8B6J (CIII). The cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB) under the respective accession numbers EMD-16184, EMD-15865, EMD-15866, EMD-15867, EMD-15868. Subtomogram average have been deposited under EMD-15900.

The atomic coordinates that were used in this study: 1NTZ [<https://www.rcsb.org/structure/1NTZ>] (cytochrome bc1), 5IY5 [<https://www.rcsb.org/structure/5IY5>] (cytochrome c), 5J4Z [<https://www.rcsb.org/structure/5J4Z>] (ovine supercomplexes)

Full versions of all gels are provided in the source file. An Excel file has been added. All the data will be publicly available.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

| | |
|-----------------------------|-----|
| Reporting on sex and gender | N/A |
| Population characteristics | N/A |
| Recruitment | N/A |
| Ethics oversight | N/A |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|-----------------|--|
| Sample size | A total of 26,063 movies were recorded and analyzed. No statistical analyses has been performed. The number of cryo-EM particles in the single dataset collected was the number of particles available. No predetermined sample size was used for other experiments. |
| Data exclusions | For cryo-EM structure determination, particles that were not respiratory supercomplex were discarded by classification, since they cannot contribute to reconstruction. |
| Replication | Cryo-EM structures were successfully obtained from three preliminary datasets. In MD simulations, at least three simulation replicas were performed. Overall, consistent results were obtained from all the different simulation replicas. |
| Randomization | Cryo-EM map resolution estimates by Fourier Shell Correlation were performed using half-maps from random half-sets. N/A to MD simulations. |
| Blinding | MD simulations did not include blinding. N/A to cryo-EM study; raw micrographs or particle images are not categorical data. Particles are randomly assigned into half-sets for image processing; hence no blinding is applicable. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | n/a | Included in the study |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |

Methods

- | n/a | Included in the study |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |